We all have to be pleased that CYDY has hired a highly qualified CRO to handle the the upcoming Phase 2 trial for inflammation. However, I'm perplexed that 11 days ago CYDY announced that it had submitted a revised protocol to the FDA for its phase 2 colorectal cancer trial without mentioning the status of the necessary CRO for that trial. Dr Jay has previously announced that that the cancer trial would be the top priority, with inflammation secondary. So what about the engagement of the vital CRO for the cancer trial? Is it possible that has already beeb addressed, one way or another?

Pure speculation on my part. I plead guilty as charged.